Search Results

Coming Soon: A Brave New World

Research is inching us closer to cures for blood cancer every day – among them, therapies that unleash the immune system, reprogramming of T-cells to track down cancer cells, and personalized treatments based on a patient’s genetic make-up.

Volunteers: The Engine Powering LLS’s Mission

I was always aware that volunteers with The Leukemia & Lymphoma Society (LLS) drive impact for blood cancer patients and families. But it wasn’t until Thanksgiving Day 2007 that I discovered the full force of their power. My wife, Holly, had recently been diagnosed with follicular lymphoma and our family was still reeling from the news. She was feeling quite ill, and we were exhausted with worry and trying to keep life as normal as possible for our two young children.

Pegaspargase

Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).

Rasburicase

Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.

Decitabine

Decitabine is FDA approved to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia.

Obecabtagene autoleucel

Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Meet the Researcher: Charlene Liao, PhD

Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancers, and what inspires their efforts to find better treatments and cures.

 

Helping Blood Cancer Patients and Caregivers Navigate the Financial Impact of COVID-19

The coronavirus (COVID-19) pandemic has been a challenging time for us all. It is especially so for cancer patients and survivors, who are at greater risk of getting sicker if they become infected with the virus because they might be immunocompromised.

Calaspargase pegol-mknl

Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. 

 

Revumenib

Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Helping Survivors Lead Longer Better Lives

Late last year I had the privilege of attending a special screening of the documentary American Symphony. The film chronicles the experiences of writer Suleika Jaouad and her husband musician Jon Batiste after learning that her acute myeloid leukemia (AML) had returned after years of remission. The movie shows how the couple navigates uncertainty, treatment, and their new normal afterwards. 

Improving Blood Cancer Survival Takes More than New Drug Discovery

In my years as a practicing hematologist-oncologist and now as chief medical officer of The Leukemia & Lymphoma Society (LLS), I’ve met many blood cancer patients who worry about how they’ll afford their treatment on top of day-to-day expenses like rent and groceries. LLS offers financial assistance for qualifying blood cancer patients and families

Targeting non-genetic mechanisms of therapeutic resistance in Acute Myeloid Leukaemia

Drug resistance in AML can develop via a non-genetic process which remains poorly understood. Using our novel cellular barcoding technology that can trace the growth of thousands of cancer cells, our research will identify genes that are switched on or off in AML cells that lead to drug resistance and relapse. This work will reveal the factors underpinning non-genetic drug resistance that may be targeted with new drugs to prevent relapse and ultimately improve quality of life and survival.

FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Leukemia

The Leukemia & Lymphoma Society Kicks Off Light The Night Fall Campaign

LLS National Research Registry Progress Report - Chronic Lymphocytic Leukemia

PhRMA Recognized as 2013 "Titan of Business & Philanthropy" At the Annual Leukemia Ball

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program

FDA Approves First Targeted Treatment for Newly Diagnosed Leukemia Subtype

Functionalizing novel PHIP variants in ancestry specific Acute Myeloid Leukemia

AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of 100 Black AML patients revealed the novel variants previously not affiliated with AML, including PHIP. Using multiomic patient sample captures and GEMMs, we will functionalize variants in PHIP and assess if they drive leukemogenesis and/or therapy resistance. The overall goal of this work is to implement inclusive genetic assessment tools for AML diagnosis.

The Leukemia & Lymphoma Society Welcomes Five Members to its Board of Directors

Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial